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Background:  Although  gastrointestinal  (GI) complications  are  receiving  more  attention  in  cardiovascular
patients  owing  to the  widespread  use  of  antithrombotic  drugs,  information  seems  to  be  limited  over  the
prevalence  of  GI  malignancies  in  those  patients.
Methods  and  results:  The  prevalence  of malignant  as  well  as non-malignant  GI lesions  diagnosed  in  cardiol-
ogy inpatients  was  investigated.  We  retrospectively  analyzed  274  cardiology  inpatients  who  underwent
upper  and/or  lower  GI tract  endoscopies.  A total  of  97 patients  (35.4%)  were  taking  multiple  antithrom-
botic  drugs  and  the  mean  number  of  antithrombotic  drugs  used  was  1.19.  Malignant  neoplasm  was  found
in 26 patients  (9.5%),  and  non-malignant  lesions  (ulcers,  adenomas,  polyps)  were  found  in  106  patients
(38.7%).  Multivariate  analysis  showed  that antiplatelet  drug  usage  was  negatively  (odds  ratio  [OR]  0.38,
95% conﬁdence  interval  [CI]  0.16–0.91)  whereas  positive  fecal  occult  blood  test  was  positively  (OR  4.44,ndoscopic screening 95% CI 1.44–13.66)  associated  with  GI  malignancies.  On the  other  hand,  for  non-malignant  GI lesions,
both  antiplatelet  drug  usage  (OR  1.85,  95%  CI  1.05–3.25)  and  positive  fecal  occult  blood  test  (OR  1.99, 95%
CI  1.14–3.47)  were  found  to be positive  predictors.
Conclusions:  During  the  59-month  study  period,  26  and  106  patients  were  diagnosed  to have GI malig-
nancies  and  non-malignant  GI  lesions,  respectively,  among  cardiology  inpatients.  Cardiology  physicians
ossib
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Combination antiplatelet medication based on different mech-
nisms has become more widely used for the treatment and
revention of atherothrombotic complications, especially after
ntracoronary stent implantation [1–3]. In addition, necessity
f anticoagulant therapy is also increasing for the prevention
f thromboembolic events in patients with atrial ﬁbrillation
4,5]. Combination antithrombotic therapy may  be beneﬁcial in
mproving prognosis in high-risk patients [6],  however, it may
ncrease gastrointestinal (GI) bleeding, a serious and poten-
ially life-threatening problem [7].  As dual or triple antiplatelet
herapy after stent implantation may  also sometimes cause
leeding complications, the appropriate duration of combination
ntiplatelet therapy must be determined by considering the bal-
nce between the effect of cardiovascular protection and the
∗ Corresponding author at: Department of Cardiovascular Medicine, University
f  Tokyo Graduate School of Medicine, Hongo 7-3-1 Bunkyo-ku, Tokyo 113-8655,
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risk of bleeding [8]. Nakagawa et al. reported that the inci-
dence of bleeding complications was signiﬁcantly increased in
patients on dual antiplatelet therapy for more than six months
[9].
On the other hand, the possibility has been discussed that
antithrombotic drug use might help to discover malignant GI
tract lesions in an early stage by unmasking bleeding from neo-
plasms [10]. GI malignancies and various cardiovascular diseases
that require antithrombotic therapy, such as coronary artery dis-
ease (CAD) and atrial ﬁbrillation, may  share common risk factors
[11–15]. Notably, Chan et al. have shown the disturbingly high
prevalence (34%) of colorectal neoplasm in patients with CAD
[16]. Cardiology physicians should not overlook the possibility of
GI malignancies even in patients taking antithrombotic drugs by
simply presuming that observed blood loss is due to clinically
insigniﬁcant GI lesions [17]. Until now, however, little informa-
tion has been available over the prevalence of GI malignancies
among cardiology inpatients in daily clinical practice. To this end,
we retrospectively analyzed the database of cardiology inpatients
who were found to have GI malignancies and non-malignant
lesions by GI endoscopic examinations, and assessed their clinical
characteristics.
vier Ltd. All rights reserved.
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Table 1
Clinical characteristics of the study patients.
Variables n = 274
Male gender, n (%) 194 (70.8)
Age, years 71.0 ± 11.5
Height, cm 159.9 ± 9.0
Weight, kg 56.7 ± 12.6
BMI, kg/m2 22.0 ± 3.8
Heart rate/min 75 ± 16
Smoking status
Never, n (%) 112 (40.9)
Former, n (%) 121 (44.2)
Current, n (%) 41 (15.0)
Hypertension, n (%) 222 (81.0)
Hyperlipidemia, n (%) 131 (47.8)
Diabetes, n (%) 117 (42.7)
Acute coronary syndrome, n (%) 45 (16.4)
Angina pectoris, n (%) 51 (18.6)
Heart failure, n (%) 108 (39.4)
Atrial ﬁbrillation, n (%) 76 (27.7)
Drugs
Antithrombotic agents
Aspirin, n (%) 143 (52.2) 34a (12.4)
Clopidogrel, n (%) 17 (6.2) 9a (3.3)
Ticlopidine, n (%) 53 (19.3) 24a (8.8)
Cilostazol, n (%) 13 (4.7) 15a (5.5)
Others, n (%) 33 (12.0) 4a (1.5)
Anticoagulants
Warfarin, n (%) 62 (22.6) 7a (2.6)
Stomach medicine
H2 blocker, n (%) 57 (20.8)
Proton pump inhibitor, n (%) 164 (59.9)
Gastric mucosa protectant, n (%) 82 (29.9)
Others, n (%) 13 (4.7)
Iron agent, n (%) 70 (25.5)
Erythropoietin, n (%) 11 (4.0)
Values are presented as the mean ± standard deviation unless stated otherwise. BMI,
body mass index.
a Newly prescribed during the current admission before endoscopic examination.
Fig. 1. Main reasons for admission to Cardiovascular Department. s/o, suspect of.82 A. Sakamoto et al. / Journal 
ethods
tudy population
The study was approved by the Ethical Committee of the
niversity of Tokyo. Between February 2005 and December 2009,
81 patients on admission to the Cardiovascular Department
nderwent upper and/or lower GI endoscopies. Of these patients,
 were known to have active cancers at the time of admission to
he department. After excluding these patients, 274 patients (194
en, 80 women) were enrolled in the current study. Assessment
f smoking status and drugs taken was made by reference to
edical records. Antiplatelet drugs included aspirin, ticlopi-
ine hydrochloride, clopidogrel sulfate, cilostazol, dipyridamole,
eraprost sodium, limaprost alfadex, ethyl icosapentate, sarpogre-
ate hydrochloride, and trapidil. Anticoagulation drugs included
arfarin.
aboratory measurements
Blood hemoglobin (Hb) levels were measured by a sodium lauryl
ulfate-hemoglobin assay. Fecal occult blood was measured by an
mmunization method using a latex agglutination assay.
astrointestinal endoscopy
All procedures for the upper and lower GI endoscopies were per-
ormed by experienced gastroenterologists in the Gastroenterology
epartment at our hospital.
tatistical analysis
Data are expressed as the mean ± standard deviation unless oth-
rwise stated. Data analysis was performed by using Dr SPSS II for
indows (SPSS Inc., Chicago, IL, USA). The t test and logistic regres-
ion analysis were applied as appropriate to assess the statistical
igniﬁcance of differences between groups. A p value of <0.05 was
aken to be statistically signiﬁcant.
esults
aseline characteristics
Of the 274 patients enrolled in the current study (Table 1),
40 underwent upper, and 128 underwent lower GI endoscopies.
4 patients underwent both upper and lower endoscopies. The
nterval between admission and performance of GI endoscopy
as 19 ± 29 days for the upper GI endoscopy and 20 ± 32 days
or the lower GI endoscopy. In the current study, patients with
nown active GI malignancies were excluded, however, 29 patients
ho had a history of curatively-treated GI malignancies were
ncluded; these curatively-treated cancers had been localized in
sophagus (4 patients), stomach (11 patients), and colorectum (12
atients; proximal colon, 2 patients; distal colon, 7 patients; rec-
um, 3 patients), and 2 patients had a history of cancers in two
ifferent locations (stomach/rectum and stomach/esophagus). The
easons for admission to the Cardiology Department are summa-
ized in Fig. 1. In 26 patients (9.5%) with progressive anemia, the
ean admission Hb levels were 8.4 ± 1.5 g/dL. Digestive symptoms
ncluded nausea, diarrhea, hematemesis, and melena. The reasons
or performing upper and/or lower GI endoscopies that were multi-
le in some patients are summarized in Fig. 2. ‘Others’ described in
ig. 2 included the investigation of the cause of chest pain, abdom-
nal pain, pericardial effusion, anorexia, and weight loss.
Fig. 2. Reasons for performing gastrointestinal (GI) endoscopy. FOBT, fecal occult
blood test.
A. Sakamoto et al. / Journal of Cardiology 61 (2013) 181–185 183
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Table 3
Multivariate analysis.
Independent variables Odds ratio (95% CI) p Value
Dependent variable: GI malignancies
Age, per year 1.03 (0.99–1.08) 0.168
Male gender 1.20 (0.46–3.16) 0.714
Admission Hb levels, per g/dL 1.07 (0.90–1.26) 0.464
Antiplatelet drug usage 0.38 (0.16–0.91) 0.030
Positive fecal occult blood test 4.44 (1.44–13.66) 0.009
Dependent variable: non-malignant GI lesions
Age, per year 1.00 (0.98–1.03) 0.966
Male gender 1.40 (0.76–2.56) 0.280
Admission Hb levels, per g/Dl 0.87 (0.77–0.97) 0.014
Antiplatelet drug usage 1.85 (1.05–3.25) 0.033
Positive fecal occult blood test 1.99 (1.14–3.47) 0.016ig. 3. Number of antithrombotic drug usage among patients who  underwent upper
astrointestinal (GI) endoscopy and those who underwent lower GI endoscopy.
ntithrombotic drug usage
Among the 274 patients, the number of antithrombotic drugs
aken was 1 in 96 patients, 2 in 66 patients, 3 in 26 patients,
 in 4 patients, and 5 in one patient. Thus, 193 (70.4%) were
aking at least one antithrombotic drug. The mean number of
ntithrombotic drugs used was calculated to be 1.19. The number
f antithrombotic drugs did not apparently differ between patients
ho underwent upper GI endoscopy and those who underwent
ower GI endoscopy (Fig. 3). Aspirin was the most frequently, and
iclopidine was the second most frequently used antiplatelet drug
t the time of admission (Table 1). The mean value of international
ormalized ratio of prothrombin time (PT-INR) in 62 patients who
ere taking warfarin at the time of admission was  1.73 ± 0.76. In
ome patients, antithrombotic drug(s) that had not been taken
efore the admission were started (Table 1). Background conditions
ecessitating such additional antithrombotic drug prescription
ncluded CAD (15 patients), post coronary stent implantation (31
atients), arrhythmia (6 patients), and others (4 patients).
I endoscopic ﬁndings
Malignant neoplasm was found in 26 patients (9.5%) (Table 2).
mong 15 patients with colorectal cancer, malignancies were
ound in proximal colon in 6 patients, distal colon in 4 patients,
ectum in 4 patients, and both proximal and distal colons in 1
atient. Among 26 patients who were found to have GI malig-
ancies, 12 patients were also diagnosed to have non-malignant
I lesions, such as polyps, adenomas, and ulcers concomitantly.
n 29 patients who had a history of curatively-treated GI malig-
ancies, no recurrent GI neoplasms were found. Non-malignant GI
esions were diagnosed in 106 patients (38.7%); GI tract ulcers that
able 2
iagnosed gastrointestinal (GI) lesions.
GI lesions n = 274
Malignant neoplasms
Esophagus, n (%) 2 (0.7)
Stomach, n (%) 9 (3.3)
Colorectum, n (%) 15 (5.5)
Non-malignant lesions
Ulcers
Esophagus, n (%) 2 (0.7)
Stomach, n (%) 26 (9.5)
Duodenum, n (%) 10 (3.6)
Colorectum, n (%) 5 (1.8)
Polyps/adenomas
Esophagus, n (%) 1 (0.4)
Stomach, n (%) 19 (6.9)
Duodenum, n (%) 5 (1.8)
Colorectum, n (%) 53 (19.3)Multivariate logistic regression analysis was performed using all the listed param-
eters as covariates.
GI, gastrointestinal; Hb, hemoglobin.
had not been previously diagnosed were found in 39 (14.2%), and
polyps/adenomas in 71 (25.9%) (Table 2). Of the 106 patients with
non-malignant GI lesions, 15 had two or more such lesions. In addi-
tion to the lesions listed in Table 2, reﬂux esophagitis, Brunner’s
gland adenoma, and colon diverticulum were found in 25 (9.1%), 2
(0.7%), and 10 (3.6%) patients, respectively.
Predictors for malignant neoplasm and non-malignant GI lesions
We then examined the various clinical parameters that may  be
associated with the malignant and non-malignant GI lesions in the
study population. The mean age did not signiﬁcantly differ between
patients who  were found to have GI malignancies (74.4 ± 7.8 years)
and those who were not (70.6 ± 11.8 years, p = 0.108). In addi-
tion, admission Hb levels did not signiﬁcantly differ between these
groups (10.6 ± 2.4 g/dL vs. 10.8 ± 2.6 g/dL, p = 0.710). Furthermore,
the prevalence of heart failure, atrial ﬁbrillation, and ischemic
heart disease did not signiﬁcantly differ between the groups. The
prevalence of GI malignancies was  borderline, but not statistically
signiﬁcantly, lower in patients who took antithrombotic drugs (14
patients [7.3%]) than in those who did not (12 patients [14.8%],
p = 0.051). On the other hand, the prevalence of GI malignancies
was signiﬁcantly lower in patients who took antiplatelet drugs (10
patients [6.1%]) than in those who did not (16 patients [14.5%],
p = 0.019). In univariate analysis, usage of antiplatelet drugs was
negatively associated with GI malignancies with an odds ratio of
0.38 (95% CI 0.17–0.88, p = 0.023), and positive fecal occult blood
test was  positively associated with GI malignancies with an odds
ratio of 2.08 (95% CI 1.20–3.58, p = 0.009). On the other hand,
usage of aspirin was  not signiﬁcantly associated with GI malig-
nancies with an odds ratio of 0.54 (95% CI 0.24–1.24, p = 0.146).
After including age, gender, and other possible confounding vari-
ables, multivariate logistic regression analysis showed that usage of
antiplatelet drugs and positive fecal occult blood test remained to
be negatively and positively, respectively, associated with GI tract
malignancies (Table 3).
Positive fecal occult blood test was found to be also a predictor
for non-malignant GI lesions; however, antiplatelet drug usage was,
unlike for GI malignancies, a positive predictor for non-malignant
GI lesions. Warfarin usage was  not found to be a signiﬁcant predic-
tor for either malignant or non-malignant GI lesions.
DiscussionWe herein report that GI malignancies and non-malignant GI
lesions (ulcers, polyps, adenomas) were diagnosed in 26 patients
(9.5%) and 106 patients (38.7%), respectively, among 274 car-
diovascular inpatients who underwent upper and/or lower GI
1 of Car
e
d
n
p
v
w
G
m
w
w
a
r
c
u
[
s
t
v
t
v
l
b
i
l
h
s
a
c
h
f
t
s
w
c
d
l
s
b
c
p
t
t
h
c
t
r
C
p
w
t
C
e
e
o
o
e
a
d
ﬁ
n
h
l
m
t84 A. Sakamoto et al. / Journal 
ndoscopies. The study population was extracted from the database
uring a 59-month period; therefore, it is calculated that GI malig-
ancies and non-malignant GI lesions were diagnosed in 0.44
atients and 1.80 patients, respectively, per month in our cardio-
ascular department, which would by no means be negligible. It
as found that antiplatelet drug usage was a negative predictor for
I malignancies, whereas it had a positive association with non-
alignant GI lesions. In addition, positive fecal occult blood test,
hich was the most frequent reason for GI endoscopic examination,
as signiﬁcantly positively associated with both GI malignancies
nd non-malignant GI lesions with an odds ratio of 4.44 and 1.99,
espectively.
Several previous studies suggested that subjects with certain
ardiovascular diseases, such as atrial ﬁbrillation [18], heart fail-
re [19], abdominal aortic aneurysm, and peripheral artery disease
20], may  have a higher risk for GI malignancies, although, most of
uch observations had been derived from small-size samples, and
hus did not seem to be conclusive. The association between cardio-
ascular diseases and GI malignancies, if present, may  be attributed
o share of common risk factors, alterations in the autonomic ner-
ous system in cancer patients [21,22], and excessive blood loss
eading to the aggravation of heart failure symptoms [23]. Of note,
y performing screening colonoscopy after coronary angiography
n more than 400 patients, Chan et al. have shown that the preva-
ence of colorectal cancer in patients with CAD was  unexpectedly
igh (4.4%), which contrasted with a much lower prevalence of
uch lesions (0.5%) in CAD-negative patients [16]. More recently, by
nalyzing the data of male subjects who underwent both coronary
omputed tomography angiography and colonoscopy as a part of
ealth check-up, Yang et al. reported that colorectal adenoma was
ound in 217 subjects (44%) among 488 total study subjects, and
hat subjects who  were found to have signiﬁcant coronary artery
tenosis had a higher rate of colorectal adenoma (odds ratio, 1.96)
hen compared with those without coronary stenosis [24]. In the
urrent study, not all the patients underwent coronary angiography
uring the study period; therefore, we cannot compare the preva-
ence of GI lesions between our population and previously reported
tudy samples.
In the current study, usage of antiplatelet drugs was  found to
e a strong negative predictor for GI malignancies. Although we
annot conclude whether antiplatelet drugs would affect GI lesion
revalence from the current observation, some possible explana-
ions, if present at all, might be as follows. First, usage of aspirin,
he most frequently used antiplatelet drug in the current study,
as been shown to reduce GI cancer risk [25,26].  Aspirin inhibits
yclooxygenase (COX), which catalyzes the rate-limiting step in
he metabolic conversion of arachidonic acid to prostaglandins and
elated eicosanoids [25]. COX exists in two isoforms, COX-1 and
OX-2, the latter of which may  promote inﬂammation and cellular
roliferation and is progressively overexpressed during the step-
ise sequence from adenoma to carcinoma [27]. Chan et al. found
hat aspirin reduces the risk of colorectal cancers that overexpress
OX-2 but not the risk of colorectal cancers with weak or absent
xpression of COX-2 [25]. Although aspirin may  exert antiprolif-
rative effects other than COX inhibition, including suppression
f nuclear factor-kB activity and induction of apoptosis, doses
f aspirin required for such non-COX-related actions are consid-
red to be higher than COX-2 inhibition [25,28]. In addition, other
ntiplatelet drugs, such as clopidogrel, ticlopidine, and cilostazol,
o not have the effect of COX-2 inhibition. Although we  did not
nd that aspirin usage was negatively associated with GI malig-
ancies, it may  be because we selected the study population who
ad already shown signs and symptoms that were suspicious of GI
esions. In addition, the population enrolled in the current study
ay  have been at higher risk for malignant GI lesions, regardless of
he suspicious signs and symptoms, because cardiovascular diseasediology 61 (2013) 181–185
and malignant neoplasm share many risk factors, such as diabetes
mellitus and smoking [16]. Therefore, it cannot be concluded that
aspirin usage would decrease the risk for GI malignancies from
the current study. Second, as antithrombotic drugs may  facilitate
hemorrhaging from non-malignant lesions [7,29–31], leading to an
increased prevalence of patients with non-malignant GI lesions
among the study population. The ﬁnding that antiplatelet drug
usage was positively associated with non-malignant GI lesions in
the current study (Table 3) may  support this notion. Interestingly,
anticoagulant (warfarin) usage was  not a positive predictor for non-
malignant GI lesions in the current study, although warfarin usage
has also been reported to increase the risk of GI bleeding [32–34].
There are several limitations in the current study. First, not all of
the participants underwent both upper and lower GI endoscopies.
Second, not all the cardiology inpatients during the study period
underwent fecal occult blood test. It is presumed that the true inci-
dence of GI malignancies may  be higher than that observed in the
current study. Third, although the rate of GI malignancies diag-
nosed by GI endoscopy among the study population was higher
than that among healthy subjects [35], cost-effectiveness of GI
endoscopic screening in cardiology patients, especially in those
with negative fecal occult blood test, may  be another issue to be
analyzed.
In conclusion, among 274 cardiology inpatients who underwent
GI endoscopies due to certain signs and symptoms, GI malignancies
were found in 26 patients (9.5%); the locations of these lesions were
stomach, 9 (3.3%), esophagus, 2 (0.7%), and colon, 15 (5.5%). Among
the study population, usage of antiplatelet drugs was negatively,
whereas positive fecal occult blood test was positively associated
with GI malignancies. Although the precise mechanism remains
unclear how antiplatelet drugs reduce GI malignancies, we  showed
here that there may  be a certain difference in the risk of GI malig-
nancies according to usage of antiplatelet drugs among cardiology
inpatients. In addition, in 106 patients, GI endoscopy revealed non-
malignant GI lesions, such as ulcers, adenomas, and polyps, some of
which were concomitantly present with GI malignancies. We have
to be aware that GI malignancies and non-malignant GI lesions may
not be a rare occurrence in cardiology inpatients. In order to avoid
overlooking such potentially life-threatening lesions, GI endoscopy
should not be ignored by simply presuming signs and symptoms
are due to clinically-insigniﬁcant GI pathologies facilitated by the
usage of multiple antithrombotic drugs.
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